Background: We compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. Methods Beginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2...
SummaryBackgroundHIV antiretroviral therapy (ART) is often managed without routine laboratory monito...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Background: We compared clinical outcomes among HIV-infected participants receiving...
To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients re...
Objectives: To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral load mo...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Objective: To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies in ...
Background. Viral load (VL) monitoring is standard of care in HIV-infected persons initiated on anti...
OBJECTIVE To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies i...
Altres ajuts: This research was supported by NIH grant R01 AI073127; by NIH grant T32 AI007433 from ...
Continued debate exists about whether initiation of antiretroviral therapy (ART) in symptom-free pat...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
BackgroundClinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive ...
SummaryBackgroundHIV antiretroviral therapy (ART) is often managed without routine laboratory monito...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Background: We compared clinical outcomes among HIV-infected participants receiving...
To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients re...
Objectives: To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral load mo...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
Objective: To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies in ...
Background. Viral load (VL) monitoring is standard of care in HIV-infected persons initiated on anti...
OBJECTIVE To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring strategies i...
Altres ajuts: This research was supported by NIH grant R01 AI073127; by NIH grant T32 AI007433 from ...
Continued debate exists about whether initiation of antiretroviral therapy (ART) in symptom-free pat...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....
BackgroundClinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive ...
SummaryBackgroundHIV antiretroviral therapy (ART) is often managed without routine laboratory monito...
INTRODUCTION The World Health Organization (WHO) recommends a CD4 cell count before starting anti...
In Africa, antiretroviral therapy (ART) is delivered with limited laboratory monitoring, often none....